Skip to main content
Caplight Logo









Igenesis

Igenesis

Private
ShanghaiHealthcare & Life Scienceshttps://www.igenesisbio.com/

Last Round

Series B

Extension

Aug 26, 2021

Total Funding Raised

$85.4M

Company Overview

Igenesis operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series B Extension round in August 2021.

Igenesis is a biotechnology company that develops and manufactures automated PCR analysis platforms, medical diagnostic tools, and nucleic acid extraction kits for healthcare and forensic applications.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotech Equipment, Precision Medicine, Biotechnology

Business Model

B2B

Customer Profile

Hardware Sales, Usage-Based SaaS

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Igenesis Comparables

Compare Igenesis with similar companies based on industry and business-model similarity.

Igenesis comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ustar Biotechnologies (Hangzhou) Ltd.
86%
Coyote Bioscience Co., Ltd.
84%
Daan Gene Co., Ltd.
76%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Igenesis Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionAug 26, 2021
Series BJun 15, 2021
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Igenesis Investors

Notable investors and investment history

Igenesis investors
InvestorRounds
Huimei CapitalSeries B Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 1, 2026

    Monthly visitors increased 627% MoM, reaching 5.7K.

Book a demo to see all signals

For institutional investors. Book with your work email.

Igenesis Filings

Explore SEC and related filing metadata, where available.

Igenesis filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Igenesis's valuation, stock price, and market status.

Is Igenesis a public or private company?

Igenesis is a private company.

What is the current stock price of Igenesis?

Igenesis is a private company, so its shares have no public market price. Caplight tracks Igenesis's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Igenesis worth (valuation)?

Valuation information for Igenesis is not publicly available.

Can I buy Igenesis stock?

Igenesis shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Igenesis's last funding round?

Igenesis's most recent funding round was Series B Extension on August 26, 2021.

Who are the main investors in Igenesis?

Key investors in Igenesis include Huimei Capital.

Will Igenesis IPO soon?

No public IPO plans have been announced for Igenesis.

How can I track Igenesis secondary market activity?

Caplight tracks bids, offers, and trades in Igenesis's shares on secondary markets.

Firmographic Details

HeadquartersShanghai
Employee Range10
Year Founded2015
Last FundingAug 26, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?